Description: ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD. Its pre-clinical products include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations for serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection treatment. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Home Page: www.immupharma.co.uk
1 Bartholomew Close
London,
EC1A 7BL
United Kingdom
Phone:
44 20 7206 2650
Officers
| Name | Title |
|---|---|
| Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA | Chairman & CEO |
| Dr. Timothy Gary Franklin M.B.A., Ph.D. | COO & Director |
| Ms. Lisa Baderoon | Head of Investor Relations & Non Executive Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2838 |
| Price-to-Sales TTM: | 22.9058 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |